Fungal echinocandin resistance.
The echinocandins are the newest class of antifungal agents in the clinical armory. These secondary metabolites are non-competitive inhibitors of the synthesis of beta-(1,3)-glucan, a major structural component of the fungal cell wall. Recent work has shown that spontaneous mutations can arise in two hot spot regions of Fks1 the target protein of echinocandins that reduce the enzyme's sensitivity to the drug. However, other strains have been isolated in which the sequence of FKS1 is unaltered yet the fungus has decreased sensitivity to echinocandins. In addition it has been shown that echinocandin-treatment can induce cell wall salvage mechanisms that result in the compensatory upregulation of chitin synthesis in the cell wall. This salvage mechanism strengthens cell walls damaged by exposure to echinocandins. Therefore, fungal resistance to echinocandins can arise due to the selection of either stable mutational or reversible physiological alterations that decrease susceptibility to these antifungal agents.
Walker
Louise A
LA
School of Medical Sciences, University of Aberdeen, Aberdeen, AB25 2ZD, UK.
Gow
Neil A R
NA
Munro
Carol A
CA
D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*; D018441:Biofilms; D002176:Candida albicans / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development / Q000378:metabolism*; D002473:Cell Wall / Q000187:drug effects / Q000378:metabolism; D025141:Drug Resistance, Fungal / Q000235:genetics / Q000502:physiology*; D054714:Echinocandins / Q000494:pharmacology* / Q000627:therapeutic use; D016681:Genome, Fungal / Q000235:genetics; D006801:Humans; D008954:Models, Biological; D009181:Mycoses / Q000188:drug therapy / Q000276:immunology
D000935:Antifungal Agents; D054714:Echinocandins